The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-24), X4 Pharmaceuticals's share price is $1.23. X4 Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was $0.31. Hence, X4 Pharmaceuticals's PB Ratio of today is 4.03.
Warning Sign:
X4 Pharmaceuticals Inc stock PB Ratio (=4.46) is close to 5-year high of 4.46
The historical rank and industry rank for X4 Pharmaceuticals's PB Ratio or its related term are showing as below:
XFOR'
s PB Ratio Range Over the Past 10 Years
Min: 0.16 Med: 0.44 Max: 4.46
Current: 3.97
During the past 9 years, X4 Pharmaceuticals's highest PB Ratio was 4.46. The lowest was 0.16. And the median was 0.44.
XFOR's PB Ratio is ranked worse than 72.82% of 1310
companies
in the Biotechnology industry
Industry Median: 2.36
vs XFOR: 3.97
During the past 12 months, X4 Pharmaceuticals's average Book Value Per Share Growth Rate was -49.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -59.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -51.40% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of X4 Pharmaceuticals was -36.40% per year. The lowest was -59.10% per year. And the median was -50.50% per year.
Back to Basics: PB Ratio
X4 Pharmaceuticals PB Ratio Historical Data
The historical data trend for X4 Pharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, X4 Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
X4 Pharmaceuticals PB Ratio Distribution
For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where X4 Pharmaceuticals's PB Ratio falls into.
X4 Pharmaceuticals PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
X4 Pharmaceuticals's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
X4 Pharmaceuticals (NAS:XFOR) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
X4 Pharmaceuticals PB Ratio Related Terms
Thank you for viewing the detailed overview of X4 Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
X4 Pharmaceuticals (X4 Pharmaceuticals) Business Description
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XFOR has been successfully added to your 